Work Has Begun on a Universal COVID-19 Vaccine – Healthline

Share Article

The vaccines for COVID-19 have saved hundreds of thousands of lives nationwide and worldwide.
In developing these safe and highly effective medicines, scientists have achieved in less than a year what can often take decades.
But the limitations of these vaccines and the unpredictability of coronavirus variants are becoming apparent.
That’s why several of the top scientists in the United States have begun working on a new and even more ambitious vaccine technology.
Current vaccines are expected to continue providing protection against severe illness, hospitalizations, and deaths due to infection with the Omicron variant.
But scientists don’t know how effective the vaccines will be against new variants that might arise.
To address this, researchers are developing universal vaccines that potentially work against all known and unknown variants and can fight multiple coronaviruses at once.
Yoshihiro Kawaoka, DVM, PhD, a virologist and professor of pathobiological sciences at the University of Wisconsin’s School of Veterinary Medicine, is one of the scientists who’s been chosen to take on this task.
Kawaoka told Healthline that he and others are working to make a vaccine that “will work on all coronaviruses and any variants.”
“We have just begun our research, but the concept works,” he added.
The idea, Kawaoka explained, is to generate an even more robust group of vaccines that fight a variety of coronaviruses with a primary focus on potential pandemic-causing coronaviruses such as SARS-CoV-2.
“This so-called ‘pan-coronavirus vaccine’ is basically preparing us for the future,” said Kawaoka.
When asked how often this vaccine would likely be given to people, he said, “We do not know yet. But ideally, it would be at most two vaccinations.”
When asked what kind of impact a pan-coronavirus vaccine could have nationwide and worldwide, he said, “I think it would be big.”
The universal vaccine pursuit began last fall when the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), allocated $36 million to three U.S. universities to develop vaccines to protect against multiple types of coronaviruses and all viral variants.
“The available COVID-19 vaccines have proven to be remarkably effective at protecting against severe disease and death,” said Dr. Anthony Fauci, the director of the NIAID, when announcing the program in September.
The pan-coronavirus vaccine development program funding went to the following:
Other collaborators include Paul Thomas, PhD, of St. Jude Children’s Research Hospital in Tennessee, and Patrick Wilson, PhD, at Weill Cornell Medicine in New York.
A key goal of the initiative is to “develop multivalent vaccine platforms and strategies suitable for use in vulnerable populations and to understand vaccine-induced responses and efficacy related to a person’s age or sex,” according to the NIH news release.
The awardees are expected to be flexible in the response to emerging knowledge about SARS-CoV-2 immune responses and factor in new information as vaccines candidates are developed.
The U.S. Army is also developing a pan-coronavirus vaccine by attaching different SARS-CoV-2 spikes to a protein called ferritin.
Last month, preclinical studies at the Walter Reed Army Institute of Research (WRAIR) showed that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed at WRAIR elicits a potent immune response and may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
Scientists in WRAIR’s Emerging Infectious Diseases Branch developed the SpFN nanoparticle vaccine based on a ferritin platform.
Dr. Kayvon Modjarrad, the director of the emerging infectious diseases branch at WRAIR, said in a press statement last month:
“Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species.”
Kawaoka said this research nationwide should also lead to other new vaccines.
“We’re working on COVID and we’re also working now on universal influenza vaccines and on Ebola vaccine clinical trials,” he said.
The Healthline News team is committed to delivering content that adheres to the highest editorial standards for accuracy, sourcing, and objective analysis. Every news article is thoroughly fact-checked by members of our Integrity Network. Furthermore, we have a zero-tolerance policy regarding any level of plagiarism or malicious intent from our writers and contributors.
All Healthline News articles adhere to the following standards:

  1. All referenced studies and research papers must be from reputable and relevant peer-reviewed journals or academic associations.
  2. All studies, quotes, and statistics used in a news article must link to or reference the original source. The article must also clearly indicate why any statistics presented are relevant.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, pricing, side effects, treatment target (e.g., HER2+), known interactions, and off-label use, if appropriate.
  4. All news articles must include original commentary from at least two qualified sources with appropriate credentials and links to relevant associations or published works.
  5. Any potential conflicts of interest related to a study or source must be clearly indicated to the reader.
  6. All news articles must include appropriate background information and context for the specific condition or topic.










OUR BRANDS

source

You might also like

Surviving 2nd wave of corona
COVID-19

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort

@voguewellness